# Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.

> **NCT00412854** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 660 (actual)

## Conditions studied

- Tetanus
- Diphtheria
- Acellular Pertussis

## Interventions

- **BIOLOGICAL:** Infanrix™/Hib
- **BIOLOGICAL:** Infanrix
- **BIOLOGICAL:** Hiberix

## Key facts

- **NCT ID:** NCT00412854
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-03
- **Primary completion:** 2007-06-01
- **Final completion:** 2007-06-25
- **Target enrollment:** 660 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00412854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00412854, "Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00412854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*